FibroSure Result Interpretation
Your FibroSure results indicate mild-to-moderate liver fibrosis (F1-F2 stage) with minimal inflammatory activity (A0-A1 grade), though the elevated alpha-2-macroglobulin level suggests the test may be overestimating fibrosis severity and should be interpreted cautiously.
Understanding Your Scores
Fibrosis Assessment
- Fibrosis Score: 0.47 (reference range 0.00-0.21)
Inflammatory Activity
- Necroinflammatory Activity Score: 0.23 (reference range 0.00-0.17)
- Grade A0-A1 indicates minimal to no active inflammation
- This suggests relatively quiet disease activity despite the fibrosis 3
Alpha-2-Macroglobulin Elevation
- Level: 302 mg/dL (reference range 110-276 mg/dL)
Clinical Significance
What This Means for You
The F1-F2 stage represents early-to-moderate liver disease that requires monitoring but typically does not indicate cirrhosis or advanced fibrosis (F3-F4). According to current guidelines, patients with F2 fibrosis should be evaluated for the underlying cause of liver disease and monitored over time 2.
Important Caveats About FibroSure Accuracy
The diagnostic accuracy of FibroSure has important limitations:
- For distinguishing F0-F1 from F2-F4 fibrosis, FibroSure shows moderate accuracy with sensitivity of 80% and specificity of 63% 4
- False positives occur in approximately 21% of cases where the test suggests significant fibrosis but biopsy shows mild disease 6
- The test performs better at excluding advanced fibrosis (F3-F4) than at precisely staging intermediate levels like F1-F2 1, 3
Why Your Alpha-2-Macroglobulin Matters
The elevated alpha-2-macroglobulin is driving your fibrosis score upward. This protein can be elevated due to:
- Actual liver fibrosis 5
- Inflammatory conditions unrelated to the liver
- Hemolysis (if blood sample was handled improperly)
- Other metabolic conditions
This means your actual fibrosis stage could be lower than F1-F2, potentially just F0-F1 (minimal or no fibrosis).
Recommended Next Steps
Immediate Actions
Identify the underlying liver disease cause
- Viral hepatitis testing (HBV, HCV)
- Metabolic liver disease evaluation (NAFLD/MASLD screening)
- Alcohol use assessment
- Autoimmune and cholestatic liver disease workup
Consider additional noninvasive testing for confirmation 2:
- FIB-4 score (calculated from age, AST, ALT, platelets) - this is recommended as first-line assessment and may provide more reliable staging
- Liver stiffness measurement via FibroScan/elastography if available
- These alternative tests can help confirm or refute the FibroSure findings
Repeat testing in 6-12 months to assess for progression, as single time-point measurements have limitations
When to Consider Liver Biopsy
Liver biopsy should be considered if 3:
- There is discordance between different noninvasive tests
- The diagnosis remains uncertain and would change management
- You have symptoms or laboratory findings suggesting more advanced disease than the FibroSure indicates
Surveillance Recommendations
For F1-F2 fibrosis 2:
- No routine hepatocellular carcinoma screening is needed (this starts at F3-F4/cirrhosis)
- No variceal screening is needed (this is for cirrhosis)
- Monitor for disease progression with repeat noninvasive testing annually or as clinically indicated
- Address modifiable risk factors (weight loss if NAFLD, alcohol cessation, treatment of viral hepatitis)
Key Takeaway
Your results suggest mild-to-moderate fibrosis without significant inflammation, but given the test's moderate accuracy at this stage and your elevated alpha-2-macroglobulin, correlation with additional noninvasive tests (particularly FIB-4) and clinical context is essential before making definitive management decisions. The good news is that F1-F2 fibrosis is potentially reversible with treatment of the underlying cause and does not carry the same risks as advanced fibrosis or cirrhosis 2.